-
Mashup Score: 18
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN University of Minnesota, Adult Blood and Marrow Transplant and Cell Therapy Program, Minneapolis, MN; Fred Hutchinson Cancer Center University of
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma (MM) is controversial. Between 2008 and 2014 a total of 217 MM patients with a median age of 51 years were included by 20 German centers within an open-label, parallel-group, multi-center clinical trial to compare alloTSCT to auto tandem transplantation TSCT (autoTSCT) followed by a 2-year maintenance therapy with thalidomide (100 mg/d) in both arms with respect to relapse/progression-free survival (PFS) and other relevant outcomes. A total of 178 patients underwent second SCT (allo n = 132 and auto n = 46). PFS at 4 years after the second SCT was 47% (CI: 38-55%) for alloTSCT and 35% (CI: 21-49%) for autoTSCT (p = 0.26). This difference increased to 22% at 8 years (p = 0.10). The cumulative incidences of non-relapse mortality (NRM) and of relapse at 4 years were 13% (CI: 8-20%) and 2% (CI: 0.3-2%) (p = 0.044) and 40% (CI: 33-50%) and 63% (CI:
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma (MM) is controversial. Between 2008 and 2014 a total of 217 MM patients with a median age of 51 years were included by 20 German centers within an open-label, parallel-group, multi-center clinical trial to compare alloTSCT to auto tandem transplantation TSCT (autoTSCT) followed by a 2-year maintenance therapy with thalidomide (100 mg/d) in both arms with respect to relapse/progression-free survival (PFS) and other relevant outcomes. A total of 178 patients underwent second SCT (allo n = 132 and auto n = 46). PFS at 4 years after the second SCT was 47% (CI: 38-55%) for alloTSCT and 35% (CI: 21-49%) for autoTSCT (p = 0.26). This difference increased to 22% at 8 years (p = 0.10). The cumulative incidences of non-relapse mortality (NRM) and of relapse at 4 years were 13% (CI: 8-20%) and 2% (CI: 0.3-2%) (p = 0.044) and 40% (CI: 33-50%) and 63% (CI:
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia - 10 day(s) ago
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy derived from thymic T-cell precursors. Approximately 40-60% of T-ALL cases exhibit aberrant overexpression of the TAL1 oncogenic transcription factor. Here, we provide a comprehensive view of the TAL1-induced transcriptional program in human T-ALL cells using a rapid protein degradation system coupled with integrative approaches. Our study demonstrates that TAL1 targets can be classified into several groups, each of which exhibits unique gene expression kinetics, chromatin features, and regulatory mechanisms. Group A genes are highly dependent on TAL1, many of which are not expressed in normal T cells or TAL1-negative T-ALL cells, representing an oncogenic TAL1 signature. The TAL1 complex predominantly activates group A genes. TAL1’s effect is not replaceable with its regulatory partners GATA3 or RUNX1. In contrast, group B genes, many of which are generally expressed across different T-ALL subgroups, exhibit dense
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 59Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application - 11 day(s) ago
B-cell acute lymphoblastic leukemia (B-ALL) remains a hard-to-treat disease with a poor prognosis in adults. Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a para-caspase required for B-cell receptor (BCR)-mediated NF-κB activation. Inhibition of MALT1 in preclinical models has proven efficacious in many B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma and diffuse large B-cell lymphoma. We sought to examine the role of MALT1 in B-ALL and determine the biological consequences of its inhibition. Targeting MALT1 with both Z-VRPR-fmk and MI-2 efficiently kills B-ALL cells independent of the cell-of-origin (pro, pre, mature) or the presence of the Philadelphia chromosome, and spares normal B cells. The mechanism of cell death was through apoptotic induction, mostly in cycling cells. The proteolytic activity of MALT1 can be studied by measuring its ability to cleave its substrates. Surprisingly, with the exception of mature B-ALL
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Haematologica - 16 day(s) ago
Open access journal of the Ferrata-Storti Foundation, a no profit organization
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 59
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Montgomery Cancer Center, Prattville Campus, Prattville, AL To create an adaptation, translation, or derivative of the original work, for commercial e-prints and printed articles further permission is required. For information contact: marketing@haematologica.org
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Department of Clinical and Molecular Medicine, Norwegian Univers ity of Science and Technology, Trondheim Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Hematology,
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia - 24 day(s) ago
Acute myeloid leukemia (AML) is a hematologic malignancy that frequently relapses, even if remission can be achieved with intensive chemotherapy. One known relapse mechanism is the escape of leukemic cells from immune surveillance. Currently, there is no effective immunotherapy for AML because of the lack of specific antigens. Here, we aimed to elucidate the association between CD155 and CD112 in AML cell lines and primary AML samples and determine the therapeutic response. Briefly, we generated NK-92 cell lines (NK-92) with modified DNAX-associated molecule 1 (DNAM-1) and T-cell immunoglobulin and ITIM domain (TIGIT), which are receptors of CD155 and CD112, respectively. Analysis of 200 cases of AML indicated that the survival of patients with high expression of CD112 was shorter than that of patients with low expression. NK-92 DNAM-1 exhibited enhanced cytotoxic activity against AML cell lines and primary cells derived from patients with AML. DNAM-1 induction in NK-92 cells enhanced
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 69Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders - 28 day(s) ago
Standard treatment for Langerhans Cell Histiocytosis (LCH) is chemotherapy, with high failure rates. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEKinhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and no data exist on their use as first-line therapy. We treated thirty-four patients (26 LCH, 2 Juvenile Xanthogranuloma, 2 Rosai-Dorfman Disease, 4 presumed single site-CNS histiocytosis) with either dabrafenib and/or trametinib, either as first line or after relapse or failure of chemotherapy. Sixteen patients aged 1.3-21 years, had disease that was recurrent or refractory to chemotherapy, 9 of whom had multisystem LCH with risk-organ involvement. With a median treatment duration of 4.3 years, 15 (94%) patients have sustained favorable responses. Eighteen patients aged 0.2-45 years received the inhibitor as first-line treatment. All of these have had sustai
Source: haematologica.orgCategories: General Medicine News, Onc News and JournalsTweet
The new study by Holtan et al. analyzes the role of amphiregulin (AREG) as a non-invasive biomarker for the risk assessment and monitoring of life-threatening acute graft-versus-host disease (GvHD). https://t.co/uiBgVs2Ack https://t.co/1OdutK7YVL